Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Prostate Cancer
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04136353
- Collaborators
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Bayer
- Cancer Trials Ireland
- Canadian Cancer Trials Group
- Memorial Sloan Kettering Cancer Center
- Prostate Cancer Clinical Trials Consortium
- Investigators
- Study Chair: Christopher Sweeney Dana-Farber Cancer Institute and Harvard Medical School Study Chair: Tamim Niazi Jewish General Hospital and McGill University
Get Well Soon